New lung research from an international team of scientists could offer doctors a new way to detect and monitor progressive lung diseases – and may also shed light on the fundamental causes of those conditions.

The research team found that immune cells called monocytes could be used to predict lung abnormalities and their progression. The more monocytes, the greater the odds there was a problem. 

The findings suggest that monocytes play a critical role in the development of interstitial lung diseases, the researchers say. These diseases scar the lungs, and the new work may help explain why that occurs.

“Previous studies have shown that certain immune cells, including monocytes, may have a critical role in the development of interstitial lung disease and have largely focused on humans who already have disease,” said researcher John S. Kim, MD, MS, a specialist in pulmonary and critical care at UVA Health who helped lead the research.

“We found that higher levels of monocytes in the blood is strongly linked to early signs of injury and scarring on lung imaging among community-dwelling adults.”

Understanding Interstitial Lung Disease

The hallmark of interstitial lung diseases is damaging inflammation. As this inflammation worsens, it can leave the lungs scarred (i.e., fibrosis) and unable to provide sufficient oxygen to the body. The most common type of interstitial lung disease is idiopathic pulmonary fibrosis. 

Approximately 30,000 to 40,000 Americans are diagnosed with idiopathic pulmonary fibrosis each year. Because it is a dangerous, progressive disease, it is important that it is caught early so that patients can receive appropriate care including treatments that can slow its progression.

The new research from Kim and his collaborators suggests that monitoring monocytes might offer a good way in the future to identify adults who may be at risk of developing idiopathic pulmonary fibrosis and other types of interstitial lung diseases.

To better understand the role of immune cells in these diseases, Kim and his colleagues looked at four large groups of people, both smokers and non-smokers – more than 7,000 people in total.

They found that those with higher monocyte counts were at higher risk for lung abnormalities and its progression over time on lung imaging. They also found that people with high monocyte counts were more likely to have reduced force volume capacity – a measure of lung function.

Overall, participants with lung abnormalities tended to have far more “activated” monocytes than those without lung abnormalities. This suggests that hyperactive monocytes may be contributing to lung injury at the early stages of this disease, the researchers conclude.

They are urging additional studies in people to better understand the role of monocytes in early interstitial lung disease.

“With further research and collaboration with other researchers, we may gain a better understanding of how monocytes contribute to the earlier stages of interstitial lung disease that can lead to future tests and therapies.,” said Kim, of UVA’s Department of Medicine.

“It is our ultimate hope to be able to identify individuals who are at higher risk of developing this condition and intervene quickly with treatments that can prevent this devastating disease.”

Findings Published

The researchers have published their findings in the American Journal of Respiratory and Critical Care Medicine. The research team consisted of Kim, Gisli Thor Axelsson, Matthew Moll, Michaela R. Anderson, Elana J. Bernstein, Rachel K. Putman, Tomoyuki Hida, Hiroto Hatabu, Eric A. Hoffman, Ganesh Raghu, Steven M. Kawut, Margaret F. Doyle, Russell Tracy, Lenore J. Launer, Ani Manichaikul, Stephen S. Rich, David J. Lederer, Vilmundur Gudnason, Brian D. Hobbs, Michael H. Cho, Gary M. Hunninghake, Christine Kim Garcia, Gunnar Gudmundsson, R. Graham Barr and Anna J. Podolanczuk. Manichaikul and Rich are part of UVA’s Center for Public Health Genomics and Department of Public Health Sciences.

The studies used as the basis for the work were made possible by the financial support of the National Institutes of Health, the National Heart, Lung and Blood Institute and other generous funders. A full list is included in the paper.

Source: University of Virginia Health System